Increased Myocardial Oxygen Consumption Reduces Cardiac Efficiency in Diabetic Mice
- Ole-Jakob How1,
- Ellen Aasum1,
- David L. Severson2,
- W.Y. Anna Chan3,
- M. Faadiel Essop3 and
- Terje S. Larsen1
- 1Department of Medical Physiology, Institute of Medical Biology, Faculty of Medicine, University of Tromsø, Tromsø, Norway
- 2Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
- 3Hatter Institute for Cardiology Research, Faculty of Medicine, Cape Town, South Africa
- Address correspondence and reprint requests to Ole-Jakob How, Department of Medical Physiology, Institute of Medical Biology, Faculty of Medicine, University of Tromsø, N-9037 Norway. E-mail: ole-jakob.how{at}fagmed.uit.no
Abstract
Altered cardiac metabolism and function (diabetic cardiomyopathy) has been observed in diabetes. We hypothesize that cardiac efficiency, the ratio of cardiac work (pressure-volume area [PVA]) and myocardial oxygen consumption (MVo2), is reduced in diabetic hearts. Experiments used ex vivo working hearts from control db/+, db/db (type 2 diabetes), and db/+ mice given streptozotocin (STZ; type 1 diabetes). PVA and ventricular function were assessed with a 1.4-F pressure-volume catheter at low (0.3 mmol/l) and high (1.4 mmol/l) fatty acid concentrations with simultaneous measurements of MVo2. Substrate oxidation and mitochondrial respiration were measured in separate experiments. Diabetic hearts showed decreased cardiac efficiency, revealed as an 86 and 57% increase in unloaded MVo2 in db/db and STZ-administered hearts, respectively. The slope of the PVA-MVo2 regression line was increased for db/db hearts after elevation of fatty acids, suggesting that contractile inefficiency could also contribute to the overall reduction in cardiac efficiency. The end-diastolic and end-systolic pressure-volume relationships in db/db hearts were shifted to the left with elevated end-diastolic pressure, suggesting left ventricular remodeling and/or myocardial stiffness. Thus, by means of pressure-volume technology, we have for the first time documented decreased cardiac efficiency in diabetic hearts caused by oxygen waste for noncontractile purposes.
- KHB, Krebs-Henseleit buffer
- MVo2, myocardial oxygen consumption
- PVA, pressure-volume area
- STZ, streptozotocin
Footnotes
-
- Accepted November 7, 2005.
- Received September 6, 2005.
- DIABETES











